Amylin Pharmaceuticals Shareholder?
Last Updated on May 1, 2020
Investigation Complete
Attorneys working with ClassAction.org have finished their investigation into this matter. Check back for any potential updates. You can also sign up for our free newsletter for the latest in class action news and settlements.
If you still have questions about your rights, contact an attorney in your area as there is a time limit for filing all lawsuits. The information on this page was posted when the investigation began and is now for reference only.
Free Consumer Tools:
- Open and Current Class Action Lawsuit Settlements and Rebates
- Open and Current Class Action Lawsuit List, Investigations
- Class Action Lawsuit and Settlement News
- Free Class Action Lawsuit Database
At A Glance
- This Alert Affects
- Amylin Pharmaceuticals Shareholders
- Damages
- Allegations have surfaced that Amylin Pharmaceuticals failed to notify shareholders that it rejected a buyout offer from Bristol-Myers Squibb for $22 per share yet the insiders then awarded themselves new low-priced options.
- Company(ies)
- Amylin Pharmaceuticals
- Additional Details
- In a shareholder derivative action, a shareholder theoretically files a claim on behalf of the corporation to protect its investors and to holder officers and directors accountable for improper management of the company.
Note: We are no longer accepting claims regarding the Amylin Pharmaceuticals shareholder derivative action.
If you are an Amylin Pharmaceuticals shareholder, you may be able to file a shareholder derivative action in light of allegations surrounding a buyout offer from Bristol-Myers Squibb. The plaintiff is this case would seek to enjoin the proposed merger of Amylin Pharmaceuticals and Bristol-Meyers Squibb claiming that because the price is too low the process is flawed. It has been alleged that in February, defendants failed to notify the Amylin Pharmaceuticals' shareholders that the company rejected a buyout offer from Bristol-Myers Squibb for $22 per share yet the insiders then awarded themselves new low-priced options.
What is a Shareholder Derivative Action?
A shareholder derivative action can be brought when it is believed that the company’s management has failed to act in the best interests of the corporation. Essentially, the plaintiff shareholder will “step into the company’s shoes” by filing their claim to protect the interests of the shareholders and to assert the corporation’s rights. In lodging such a claim, a sole investor may be able to induce company-wide change which otherwise might not have occurred, including the nurturing of corporate governance reform for the benefit of shareholders, the removal of board members who injured the company, and the award of monetary damages.
Can You Bring a Claim?
If you are an Amylin Pharmaceuticals shareholder and are interested as serving as a plaintiff in this potential action, fill out our free case review form today for more information. These types of claims protect the rights of shareholders, hold officers and directors accountable for their wrongdoings, and enhance corporate governance at businesses throughout the nation. We are looking forward to hear from investors who stress the need for liability and honesty in corporate boardrooms and look to take a stand against alleged corporate fraud and misconduct.
Before commenting, please review our comment policy.